化合物 PTC-209|T2345|TargetMol

PTC-209
315704-66-6

￥355 1mg 起订

￥823 5mg 起订

￥1220 10mg 起订

上海更新日期：2024-09-30

TargetMol中国（陶术生物）

VIP3年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 化合物 PTC-209

英文名称：: PTC-209

CAS号：: 315704-66-6

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99.60%

产品类别：: 抑制剂

货号：: T2345

Product Introduction

Bioactivity

名称	PTC-209
描述	PTC-209 is a potent and selective BMI-1 inhibitor.
细胞实验	To determine whether pretreatment with the inhibitor affects tumor cell growth, cells are plated with the inhibitor for 4 d in vitro and plated in limiting doses in vitro without adding further inhibitor. Trypan blue exclusion is used to count viable cells. The in vitro sphere-initiating cell frequency is calculated after inhibitor treatment by evaluating the number of wells containing spheres. For the experiments where LDAs are set up following recovery of PTC-209 treated cells, 6-well plates were seeded with 1E6 cells per well and incubated overnight. Cells are subsequently treated for 4 d in triplicate with either DMSO vehicle or PTC-209 (0.01, 0.1, 1 and 10 μM). Drug treatments are washed off and 4 mL fresh suspension medium added to all wells. To assess cell viability following the 4 d treatment window, cells are trypsinized and counted at 0, 24, 72 and 120 h after removal of the drug. Long-lasting effects of the drug treatment on sphere-forming ability are assessed by plating LDAs (50,000, 10,000, 1,000,100, 10 and 1 cell per well) using the cells obtained 120 h after the 4-d drug treatment.(Only for Reference)
激酶实验	Untranslated region-mediated luciferase reporter expression: HEK293 cells are transfected with a GEMS reporter vector that contains the luciferase open-reading frame flanked by and under post-transcriptional control of the BMI-1 5′ and 3′ UTRs. The resulting stable cells (F8) are treated with PTC-209 or vehicle control overnight, and then luciferase reporter activity is determined using Bright-Glo assays. The assays are run in triplicate for each point, and the percentage of inhibition was calculated against vehicle control.
体外活性	PTC-209能降低体内功能性的结直肠癌CICs的频率.PTC-209（60 mg/kg/day,s.c.）有效地抑制肿瘤组织中BMI-1的产生,并停止在具有原代人结肠癌异种移植物,人结肠癌细胞系LIM1215或HCT116异种移植物的小鼠中预先建立的肿瘤的生长.
体内活性	PTC-209通过不可逆的生长抑制破坏结肠直肠癌起始细胞（CIC）。PTC-209抑制人结肠直肠HCT116和人纤维肉瘤HT1080肿瘤细胞中UTR介导的报道基因表达和内源性BMI-1表达。PTC-209以BMI-1依赖性减少直肠肿瘤细胞的生长。
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	Ethanol : 9.9 mg/mL (20 mM) DMSO : 50 mg/mL (100.97 mM), Sonication is recommended.
关键字	tumor \| PTC-209 \| lung \| Inhibitor \| inhibit \| HEK293T \| colon \| CICs \| cells \| cancer-initiating \| breast \| Autophagy \| anti-myeloma
相关产品	Guanidine hydrochloride \| Naringin \| Valproic Acid \| Taurine \| Gefitinib \| Aceglutamide \| Hydroxychloroquine \| Curcumin \| Stavudine \| Salicylic acid \| Paeonol \| Sodium 4-phenylbutyrate
相关库	抑制剂库 \| 抗癌活性化合物库 \| 经典已知活性库 \| 抗癌化合物库 \| 已知活性化合物库 \| 细胞周期化合物库 \| 自噬库 \| 抗结直肠癌化合物库 \| 抗衰老化合物库 \| NO PAINS 化合物库 \| DNA 损伤和修复分子库 \| 表型筛选靶点鉴定库

PTC209|||PTC 209|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

化合物 PTC-209相关厂家报价

BMI-1抑制剂(PTC-209)
上海泽叶生物科技有限公司 VIP
2024-11-12
询价

PTC-209
上海芮晖化工科技有限公司 VIP
2024-11-08
询价

aladdin 阿拉丁 P287327 PTC 209,Bmi-1抑制剂 315704-66-6 ≥98%(HPLC)
上海阿拉丁生化科技股份有限公司 VIP
2024-08-16
￥1544.90

PTC-209
广州贝尔卡生物科技有限公司
2024-03-04
询价

内容声明